autophagy related 14Genealiases: ATG14L · BARKOR · KIAA0831
Q-omics provides the consensus-scored ATG14 profile across patient tissues and cancer cell-line models. ATG14 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, ATG14 is differentially expressed in 10, with the highest sampling consensus in LIHC. Additionally, ATG14 RNA expression shows 21,483 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight ACC, and LIHC as cancer lineages where ATG14 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ATG14 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ATG14 survival associations across molecular data types. ATG14 RNA expression shows survival associations in the most cancer types (22), followed by mutation status (5) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ATG14 RNA expression–survival associations across cancer types. High ATG14 expression shows unfavorable associations in ACC, KICH and UVM, but favorable associations in BRCA, KIRC and UCS. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for ATG14 RNA expression.
This table summarizes ATG14 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10, while mass-spec protein shows differences in 5. The strongest signals are observed in LIHC for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for ATG14. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ATG14 shows lower tumor expression in THCA and BRCA and higher tumor expression in LIHC, HNSC, CHOL and LUSC. The LIHC box plot shows higher ATG14 RNA expression in tumor versus normal tissue (log2 FC = +1.026, t-test p < 0.001).
This table shows molecular features associated with ATG14 in patient tissues and cancer cell lines. In patient samples, ATG14 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, ATG14 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SKIN, while CRISPR and shRNA rows add functional-dependency signals in OESOPHAGUS and BLOOD_Lymphoma.
